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Aim To evaluate the impact of pharmacotherapeutic ed-
ucation on 30-day post-discharge medication adherence 
and adverse outcomes in patients with type 2 diabetes 
mellitus (T2DM).
Methods The prospective, randomized, single-center 
study was conducted at the Medical Department of Uni-
versity Hospital Dubrava, Zagreb, between April and June 
2018. One hundred and thirty adult patients with T2DM 
who were discharged to the community were randomly 
assigned to either the intervention or the control group. 
Both groups during the hospital stay received the usual 
diabetes education. The intervention group received ad-
ditional individual pre-discharge pharmacotherapeutic 
education about the discharge prescriptions. Medication 
adherence and occurrence of adverse outcomes (adverse 
drug reactions, readmission, emergency department visits, 
and death) were assessed at the follow-up visit, 30 days af-
ter discharge.
Results The number of adherent patients was significantly 
higher in the intervention group (57/64 [89.9%] vs 41/61 
[67.2%]; χ2 test, P = 0.003]. There was no significant differ-
ence between the groups in the number of patients who 
experienced adverse outcomes (31/64 [48.4%] vs 36/61 
[59.0%]; χ2 test, P = 0.236). However, higher frequencies of 
all adverse outcomes were consistently observed in the 
control group.
Conclusion Pharmacotherapeutic education of patients 
with T2DM can significantly improve 30-day post-dis-
charge medication adherence, without a significant reduc-
tion in adverse clinical outcomes.
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Type 2 diabetes mellitus (T2DM) is a chronic progressive 
disease, affecting more than 400 million people world-
wide (1). In addition to lifestyle modification, most T2DM 
patients need pharmacotherapy to achieve adequate gly-
cemic control (2). Additional pharmacotherapy is usually 
needed for the treatment of frequently present concom-
itant diseases and risk factors. However, polytherapy in-
creases the risk of adverse drug reactions (ADRs) (3). One 
prospective observational study in a tertiary-care hospital 
found ADRs in 11.8% of patients with diabetes (4). Many 
patients experience ADRs soon after hospital discharge, 
which may be attributed to the pharmacotherapy chang-
es during hospitalization (5). These ADRs can result in ear-
ly readmission and emergency department (ED) visits. An 
Italian study reported ADRs in 73.8% of patients taking oral 
antidiabetic drugs within one month of study enrollment 
(6). However, between 11% and 38% of ambulatory ADRs 
is preventable (7).
Medication adherence improves glycemic control and clin-
ical outcomes, and lowers T2DM treatment costs (8,9). The 
adherence rates to diabetes medications vary from 31% 
to 87% in retrospective studies and from 53% to 98% in 
prospective studies (10). Factors affecting medication ad-
herence include age, race, health beliefs, medication cost, 
co-pays, and others. Medication adherence is lower in the 
case of ADRs and if medications are taken more than twice 
daily, with concomitant depression and skepticism about 
the importance of medication (9,11).
A 30-day readmission rate has been used as a measure 
of health care quality (12). Patients who were discharged 
from hospital with the diagnosis of diabetes had a signifi-
cantly higher 30-day readmission rate than patients with-
out diabetes (13). Patients with diabetes are also more like-
ly to be readmitted with other comorbid conditions, such 
as heart failure, myocardial infarction, and cardiac surgery 
(14). Many readmissions are drug-related, resulting from 
ADRs and non-adherence, and are potentially preventable 
(15,16). Between 40% and 57% of readmissions caused by 
ADRs, and all readmissions caused by non-adherence can 
be prevented (15,17).
Education and counseling of DM patients improves medi-
cation adherence and clinical outcomes (9,18,19). Phar-
macotherapeutic education, as part of a comprehensive 
education of patients with T2DM, is focused on proper 
medication use and prevention and early detection of 
ADRs. However, there are no randomized studies evaluat-
ing the effect of pharmacotherapeutic education on medi-
cation adherence and adverse outcomes in patients with 
T2DM. Our hypothesis was that pharmacotherapeutic ed-
ucation of T2DM patients can improve medication adher-
ence and decrease the incidence of adverse clinical out-
comes. Therefore, the aim of this study was to evaluate the 
impact of pharmacotherapeutic education on the 30-day 
post-discharge medication adherence and adverse out-
comes, including ADRs, readmissions, ED visits, and death 
in patients with T2DM.
PaTIeNTS aNd MeThOdS
This prospective, randomized, single-center study was 
conducted at the Medical Department of University Hospi-
tal Dubrava, Zagreb, Croatia between April and June 2018. 
The protocol was approved by the University Hospital Du-
brava Ethics Committee (March 20, 2017). The quality of 
the study was assessed according to the CONSORT 2010 
checklist (20). Before the recruitment, all patients gave 
their written informed consent.
Patients
The inclusion criteria were age of 18 years or older, T2DM 
diagnosis, and hospital discharge to the community. The 
exclusion criteria were cognitive disorders interfering with 
participation; terminal illness with a life expectancy <1 
month; transfer to other hospitals or discharge to a long-
term care facility; and refusal to participate in the study 
(Figure 1). The outcome measures were medication adher-
ence and adverse outcomes (ADRs, readmission, ED visit, 
and death) 30 days after hospital discharge.
Methods
Data on patients’ age and sex, prescribed medications, and 
discharge diagnoses were collected from the medical re-
cords and entered into a Microsoft Excel-based database 
(Microsoft, Redmond, WA, USA). The included patients 
were randomized to the intervention or control group in 
a 1:1 ratio using a random number list generated in Mi-
crosoft Office Excel 2010® (RAND function). Both groups 
during the hospital stay received standardized diabetes 
education, including education about the disease, diet, 
physical activity, alcohol intake, smoking, diabetes medica-
tions, glucose self-monitoring, and acute and chronic dia-
betes complications.
The intervention group received additional individu-
al pre-discharge pharmacotherapeutic education 
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about the discharge prescriptions. During 30-minute ses-
sions, patients were informed by a qualified physician 
about each prescribed medication, including indications 
for medication prescription, dosage and administration 
time, the importance of medication adherence, possible 
consequences of non-adherence, possible ADRs, preven-
tion and early detection of ADRs, and measures to be taken 
if an ADR is suspected. All patients were given a leaflet con-
taining the same information in writing (21).
Patients from both groups were discharged from the hos-
pital according to the standard procedure and given a dis-
charge letter, listing discharge diagnoses, interventions, 
and current medications. The follow-up visit was sched-
uled 30 days (±5 days) after discharge. If a patient did not 
attend the visit, the investigator consulted his or her family 
or general practitioner to exclude the possibility of death.
At the visit, a qualified physician blinded to the study in-
tervention assessed the patient’s medication adherence 
and occurrence of adverse outcomes (ADRs, readmission, 
and ED visits). The patients were asked to bring all the re-
maining medications and empty packaging. Medication 
adherence was assessed by pill count method (22). The 
results were presented as a categorical variable: adher-
ent (adherence 80%-100%) vs non-adherent (adherence 
<80% or >100%).
To assess the occurrence of adverse outcomes, the pa-
tients were asked if after hospital discharge they had had 
any new or worsening symptoms, hospital readmissions, 
or ED visits. After the interview, the patients were exam-
ined for signs of ADRs. If an adverse outcome was report-
ed or suspected, supporting medical documentation was 
evaluated.
FIGuRe 1. Study flow-chart.
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Medical records in the computerized hospital database 
were reviewed for all patients included in the study. The 
records, filled out by hospital physicians, contain data on 
hospitalizations, ED visits, and outpatient visits, labora-
tory test results, and radiographic, electrocardiographic, 
and pathologic findings. If the patient’s medical docu-
mentation did not contain enough information on ED 
visit or admission to another hospital, or if the patient 
died, the investigator consulted patient’s general prac-
titioner and family. The physician assessed the cause of 
hospital readmission, ED visit, or death. New or worsen-
ing signs or symptoms, or asymptomatic abnormalities 
shown by laboratory test results, were considered an 
ADR if they received the Naranjo scale rating “Possible” or 
higher (23). Patients were considered to have achieved 
the study outcome if they experienced any of the men-
tioned adverse events (ADRs, readmission, ED visits, and 
death).
Statistical analysis
The sample size was calculated before the beginning of 
the study on the basis of literature data and previous expe-
rience. The expected proportion of non-adherent patients 
was 10% in the intervention and 30% in the control group 
(21). Type I error was set at 0.05 and type II error at 0.2 (80% 
power). Using the χ2 test, the needed total sample size was 
calculated to be 124 patients (62 patients per group).
Normality of distribution of numerical variables was test-
ed using the Shapiro-Wilk test. Numerical variables are 
expressed as median and interquartile range (IQR) or 
mean ± standard deviation (SD). The differences between 
groups for numerical variables were compared using the 
Mann-Whitney U test or t test, where appropriate, and for 
categorical variables using the χ2 test or the Fisher test. The 
level of significance was set at P < 0.05. Statistical analysis 
TaBLe 1. Characteristics of patients with type 2 diabetes mellitus (T2dM) included in the study*
No. (%) of T2dM patients
Characteristics intervention group (n = 64) control group (n = 61) P
age (years; median, IQR) 72 (65-78) 71 (65-76) 0.449
Sex
male 29 (45.3) 26 (42.6) 0.762
female 35 (54.7) 35 (57.4)
No. of prescribed drugs (mean±Sd) 7.5 ± 2.9 7.3 ± 3 0.701
Most frequent drug classes
oral antidiabetic drugs 38 (59.4) 34 (55.7) 0.681
angiotensin converting enzyme inhibitor 36 (56.3) 39 (63.9) 0.381
diuretic 35 (54.7) 36 (59.0) 0.625
beta blocker 35 (54.7) 28 (45.9) 0.326
statin 33 (51.6) 31 (50.8) 0.934
calcium channel blocker 33 (51.6) 25 (41.0) 0.236
insulin 30 (46.9) 33 (54.1) 0.419
acetylsalicylic acid 29 (45.3) 29 (47.5) 0.803
proton pump inhibitor 26 (40.6) 21 (34.4) 0.474
potassium 17 (26.6) 17 (27.9) 0.870
No. of discharge diagnoses (median, IQR)  5 (4-6)  5 (4-5) 0.336
Most frequent diagnoses
hypertension 56 (87.5) 49 (80.3) 0.274
hyperlipidemia 20 (31.3) 12 (19.7) 0.138
atrial fibrillation 13 (20.3) 10 (16.4) 0.572
chronic kidney disease 13 (20.3)  8 (13.1) 0.282
heart failure  9 (14.1) 12 (19.7) 0.402
myocardial infarction  8 (12.5)  7 (11.5) 0.860
urinary tract infection  7 (10.9) 11 (18.0) 0.259
gastroesophageal reflux disease  7 (10.9) 10 (16.4) 0.374
hypothyroidism  7 (10.9)  7 (11.5) 0.924
*IQR – interquartile range, Sd – standard deviation.
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and sample size calculation were performed using Med-
Calc Statistical software, version 17.9.6 (MedCalc Software 
bvba, Ostend, Belgium).
ReSuLTS
The study included 130 patients (65 in the intervention 
and 65 in the control group). One patient in the interven-
tion and 4 patients in the control group were lost to follow-
up (Figure 1). The groups did not differ according to age, 
sex, the number of discharge diagnoses, or the number of 
discharge drugs (Table 1).
There were significantly more adherent patients in the in-
tervention than in control group (57/64 [89.9%] vs 41/61 
[67.2%]; odds ratio [OR] = 3.97, P = 0.003). There was no sig-
nificant difference in the number of patients who experi-
enced adverse outcomes. However, higher frequencies of 
all adverse outcomes were consistently observed in the 
control group (Table 2). The groups did not significantly 
differ in the number of adverse outcomes per patient (me-
dian 0 vs 1 for intervention and control group, respective-
ly). There was no significant difference in the number of 
particular ADRs between the groups (Table 3).
Post-hoc sample size calculations based on our results, 
type I error of 0.05 and type II error of 0.2, suggest that 102 
patients would be needed to confirm the difference be-
tween the groups in adherence, 694 patients to confirm 
the difference in adverse outcomes, and 2856 patients to 
confirm the difference in ADRs.
dISCuSSION
The presented results indicate that pharmacotherapeutic 
education can significantly improve medication adher-
ence in patients with T2DM. However, improved medica-
tion adherence did not significantly reduce the occurrence 
of adverse clinical outcomes. Thus, our hypothesis cannot 
be affirmed.
The intervention group in our study had 22.7% higher 
medication adherence compared to controls. Previous 
studies on interventions to improve medication adher-
ence had similar results (9). Pharmacotherapeutic educa-
tion improves medication adherence by improving pa-
tient’s comprehension of ADRs, and treatment regimen 
and benefits (11).
Several studies showed a positive correlation between 
medication adherence and adequate clinical outcomes 
in patients with T2DM; patients with better medication 
adherence more frequently attained treatment targets 
for HbA1c, blood pressure, and low-density lipoprotein 
cholesterol (24-26). Although in the present study the 
number of patients experiencing ADRs, readmission, ED 
visit, or death was higher in the control than in interven-
tion group, the difference was not significant. In con-
TaBLe 2. Rates of 30-day post-discharge adverse outcomes, including adverse drug reactions, readmissions, emergency department 
visits, and death in patients with type 2 diabetes mellitus (T2dM) included in the study
No. (%) of T2dM patients
adverse outcome intervention group (n = 64) control group (n = 61) P
Total 31 (48.4) 36 (59.0) 0.236
Adverse drug reactions 23 (35.9) 25 (41.0) 0.562
Readmission  5 (7.8)  8 (13.1) 0.332
Emergency department visit 14 (21.9) 15 (24.6) 0.719
Death  1 (1.6)  3 (4.9) 0.357
TaBLe 3. Types of 30-day post-discharge adverse drug reactions in patients with type 2 diabetes mellitus (T2dM) included in the 
study
No. (%) of T2dM patients
adverse drug reactions intervention group (n = 64) control group (n = 61) P
Hypoglycemia 11 (17.2) 16 (26.2) 0.219
Hypotension  3 (4.7)  1 (1.6) 0.619
Coagulopathy  2 (3.1)  2 (3.2) 1.000
Statin induced myopathy  2 (3.1)  0 (0) 0.496
Other  5 (7.8)  6 (9.8) 0.690
295Marušić et al: Education on medication adherence and adverse outcomes in T2DM patients
www.cmj.hr
trast with this result, meta-analysis by Khunti et al (27) in 
adults with T2DM found that adherence ≥80% was asso-
ciated with a significant reduction of all-cause mortality 
and hospitalization risk. Furthermore, Kuo et al (28) re-
ported that poor adherence to diabetic medications was 
associated with increased all-cause mortality and diabe-
tes-related deaths. The lack of association between bet-
ter medication adherence and adverse outcomes in this 
study can be explained by a relatively short follow-up pe-
riod. A longer follow-up might have enabled us to detect 
a full effect of adherence improvement on adverse out-
come (29).
Although pharmacotherapeutic education in this study 
was conducted by a physician, education conducted by 
clinical pharmacists or nurses also effectively improves 
medication adherence (30,31). Moreover, effective educa-
tion could also be conducted over the telephone (32).
Diabetes counseling and education can slightly increase the 
risk of hypoglycemic events (18). However, in this study the 
number of patients with detected hypoglycemia was lower 
in the intervention group. Although the difference was not 
significant, it might be clinically significant considering the 
possible consequences of hypoglycemic events in the el-
derly. These results are in accordance with a previous study 
suggesting that many ADRs can be prevented (7).
A limitation of the study is that some adverse outcomes 
might not have been detected due to patients’ forgetful-
ness and incomplete medical records. We were also un-
able to control the type of information patients received 
from their physicians, which might have resulted in het-
erogeneity in patients’ knowledge. Furthermore, since 
patients filled their prescriptions in community pharma-
cies, counseling with pharmacists might have influenced 
medication adherence and biased the study results. Oc-
currence of adverse outcomes might have been influ-
enced by diabetes duration, which was not evaluated in 
this study.
Adherence to medication therapy is essential in T2DM con-
trol, since low adherence might negatively affect clinical 
outcomes (33). To our knowledge, this is the first prospec-
tive, randomized study evaluating the effect of pharmaco-
therapeutic education on medication adherence and ad-
verse clinical outcomes in patients with T2DM. Results of 
this study support the implementation of pharmacothera-
peutic education as an important part of comprehensive 
T2DM education.
Oxford Centre for evidence-based Medicine level of evidence: 2.
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